Literature DB >> 22969967

Interferon-γ enhances promyelocytic leukemia protein expression in acute promyelocytic cells and cooperates with all-trans-retinoic acid to induce maturation of NB4 and NB4-R1 cells.

Pengcheng He1, Yanfeng Liu, Mei Zhang, Xiaoning Wang, Jieying Xi, DI Wu, Jing Li, Yunxin Cao.   

Abstract

In order to investigate the effect and mechanisms of interferon (IFN)-γ in combination with all-trans-retinoic acid (ATRA) on NB4 cells [ATRA-sensitive acute promyelocytic leukemia (APL) cell line] and NB4-R1 cells (ATRA-resistant APL cell line) and to search for a novel approach to solve the problem of ATRA resistance in APL, we initially treated NB4 and NB4-R1 cells with IFN-γ, ATRA and IFN-γ in combination with ATRA, respectively. The cell proliferation was then tested by MTT assay, and the cell differentiation was tested through light microscopy, by NBT test and flow cytometry (FCM). The expression of promyelocytic leukemia (PML) protein was observed by indirect immune fluorescent test. Results showed that ATRA inhibited the growth of NB4 cells, however, it could not inhibit the growth of NB4-R1 cells. IFN-γ inhibited the growth of both NB4 and NB4-R1 cells. Meanwhile, the growth inhibition effect of IFN-γ in combination with ATRA on both NB4 and NB4-R1 cells was significantly stronger than that of any single drug treatment. The results of the NBT reduction test and CD11b antigen detection by FCM indicated that IFN-γ induces the differentiation of NB4 and NB4-R1 cells to some extent. Moreover, the maturation degree of both NB4 and NB4-R1 cells induced by IFN-γ in combination with ATRA was more significant than that of IFN-γ or ATRA alone. After treatment with IFN-γ, the number of fluorescent particles in NB4 and NB4-R1 cell nuclei was higher than those in the control group, which indicated that IFN-γ may induce the expression of PML protein. Together, IFN-γ augments the proliferation inhibition effect of ATRA on NB4 and NB4-R1 cells through enhancing the expression of PML protein. IFN-γ in combination with ATRA not only strengthens the induction differentiation effect of ATRA on NB4 cells, but also can partially induce the maturation of NB4-R1 cells with ATRA resistance.

Entities:  

Year:  2012        PMID: 22969967      PMCID: PMC3438595          DOI: 10.3892/etm.2012.488

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  30 in total

1.  The co-expression of PML/RAR alpha and AML1/ETO fusion genes is associated with ATRA resistance.

Authors:  Rodrigo Siqueria Abreu e Lima; Marcelo Rozera Baruffi; Ana Sílvia Gouveia de Lima; Fá Morato de Oliveira; Lorena Lôbo de Figueiredo-Pontes; Luiz Gonzaga Tone; Sílvia Regina Rogatto; Roberto Passetto Falcao; Maria de Lourdes L Ferrari Chauffaille; Eduardo M Rego
Journal:  Br J Haematol       Date:  2005-02       Impact factor: 6.998

Review 2.  Rabies viral mechanisms to escape the IFN system: the viral protein P interferes with IRF-3, Stat1, and PML nuclear bodies.

Authors:  Mounira K Chelbi-Alix; Aurore Vidy; Jamila El Bougrini; Danielle Blondel
Journal:  J Interferon Cytokine Res       Date:  2006-05       Impact factor: 2.607

3.  Role of PML in cell growth and the retinoic acid pathway.

Authors:  Z G Wang; L Delva; M Gaboli; R Rivi; M Giorgio; C Cordon-Cardo; F Grosveld; P P Pandolfi
Journal:  Science       Date:  1998-03-06       Impact factor: 47.728

4.  [Study on the synergic effect of all-trans retinoic acid combined with IFN-alpha on the proliferation and differentiation of HL-60 cells].

Authors:  Chang-hai Liu
Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi       Date:  2005-09

5.  Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.

Authors:  Andreas Burchert; Martin C Müller; Philippe Kostrewa; Philipp Erben; Tilman Bostel; Simone Liebler; Rüdiger Hehlmann; Andreas Neubauer; Andreas Hochhaus
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

6.  Pharicin B stabilizes retinoic acid receptor-α and presents synergistic differentiation induction with ATRA in myeloid leukemic cells.

Authors:  Zhi-Min Gu; Ying-Li Wu; Mei-Yi Zhou; Chuan-Xu Liu; Han-Zhang Xu; Hua Yan; Yong Zhao; Ying Huang; Han-Dong Sun; Guo-Qiang Chen
Journal:  Blood       Date:  2010-08-25       Impact factor: 22.113

7.  Transfection of promyelocytic leukemia in retrovirus vector inhibits growth of human bladder cancer cells.

Authors:  Lei Li; Da-lin He
Journal:  Acta Pharmacol Sin       Date:  2005-05       Impact factor: 6.150

Review 8.  Interferon-alpha in the treatment of multiple myeloma.

Authors:  Teh Liane Khoo; Annette Juul Vangsted; Douglas Joshua; John Gibson
Journal:  Curr Drug Targets       Date:  2011-03-01       Impact factor: 3.465

9.  Neuroprotective effects of cyclooxygenase-2 inhibitor celecoxib against toxicity of LPS-stimulated macrophages toward motor neurons.

Authors:  Yong Huang; Jing Liu; Li-zhen Wang; Wei-yu Zhang; Xing-zu Zhu
Journal:  Acta Pharmacol Sin       Date:  2005-08       Impact factor: 6.150

10.  Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL).

Authors:  Vikas Gupta; Qi-long Yi; Joseph Brandwein; Jeffrey H Lipton; Hans A Messner; Andre C Schuh; Richard A Wells; Mark D Minden
Journal:  Leuk Res       Date:  2005-01       Impact factor: 3.156

View more
  3 in total

1.  LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia.

Authors:  X Wang; Q Lin; F Lv; N Liu; Y Xu; M Liu; Y Chen; Z Yi
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

2.  Combined staurosporine and retinoic acid induces differentiation in retinoic acid resistant acute promyelocytic leukemia cell lines.

Authors:  Dong-zheng Ge; Yan Sheng; Xun Cai
Journal:  Sci Rep       Date:  2014-04-28       Impact factor: 4.379

Review 3.  PLZF-RARα, NPM1-RARα, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review.

Authors:  Marta Sobas; Maria Carme Talarn-Forcadell; David Martínez-Cuadrón; Lourdes Escoda; María J García-Pérez; Jose Mariz; María J Mela-Osorio; Isolda Fernández; Juan M Alonso-Domínguez; Javier Cornago-Navascués; Gabriela Rodríguez-Macias; María E Amutio; Carlos Rodríguez-Medina; Jordi Esteve; Agnieszka Sokół; Thais Murciano-Carrillo; María J Calasanz; Manuel Barrios; Eva Barragán; Miguel A Sanz; Pau Montesinos
Journal:  Cancers (Basel)       Date:  2020-05-21       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.